Wilfried Seifert
Overview
Explore the profile of Wilfried Seifert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
164
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mahlangu J, Mancuso M, Fischer K, Djambas Khayat C, Carvalho M, Karim F, et al.
Haemophilia
. 2025 Feb;
PMID: 39917944
Introduction: Clinical trials and real-world evidence have demonstrated the efficacy and safety of rVIII-SingleChain in previously treated patients with haemophilia A. Aim: To investigate the safety and efficacy of rVIII-SingleChain...
2.
Ay C, Napolitano M, Hassoun A, Tomic R, Martin C, Seifert W, et al.
Haemophilia
. 2024 Mar;
30(3):577-588.
PMID: 38549463
Introduction: Consensus over the definition of recombinant factor VIII (rFVIII) product classification in haemophilia A is lacking. rFVIII products are often classified as standard half-life (SHL) or extended half-life (EHL);...
3.
Lemons R, Wang M, Curtin J, Lepatan L, Male C, Peyvandi F, et al.
TH Open
. 2024 Mar;
8(1):e155-e163.
PMID: 38532939
Recombinant fusion protein linking coagulation factor IX (FIX) with albumin (rIX-FP) has been shown to be an effective, well-tolerated treatment for patients with severe hemophilia B who had previously received...
4.
Pabinger I, Lissitchkov T, Nagao A, Lepatan L, Li Y, Seifert W, et al.
Res Pract Thromb Haemost
. 2023 Aug;
7(4):100195.
PMID: 37538501
Background: Extended half-life factor IX (FIX) products have revolutionized prophylactic treatment for patients with hemophilia B as patients maintain protective FIX levels with minimal occurrence of spontaneous bleeding. rIX-FP is...
5.
Laws H, Fukutake K, Lopez-Fernandez M, Li Y, Seifert W, Tagliaferri A
Eur J Haematol
. 2023 May;
111(2):293-299.
PMID: 37232041
Objective: To assess the impact of prophylaxis with rIX-FP, a fusion protein linking recombinant factor IX (FIX) with human albumin, on joint outcomes. Methods: Joint outcomes were assessed in pediatric...
6.
Escobar M, Mancuso M, Hermans C, Leissinger C, Seifert W, Li Y, et al.
J Clin Med
. 2022 Feb;
11(4).
PMID: 35207344
Hemophilia B is a bleeding disorder caused by a deficiency of coagulation factor IX (FIX). Treatment with FIX replacement products can increase FIX activity levels to minimize or prevent bleeding...
7.
Djambas Khayat C, Iosava G, Romashevskaya I, Stasyshyn O, Lopez M, Pompa M, et al.
J Blood Med
. 2021 Jun;
12:483-495.
PMID: 34188580
Background: Plasma-derived von Willebrand factor/factor VIII (pdVWF/FVIII; VONCENTO, CSL Behring) is a high-concentration, low-volume, high-purity concentrate, with a high level of VWF high-molecular-weight multimers and a VWF/FVIII ratio of ~2.4:1....
8.
Lissitchkov T, Klukowska A, Buevich E, Maltceva I, Auerswald G, Stasyshyn O, et al.
J Blood Med
. 2020 Oct;
11:345-356.
PMID: 33117020
Objective: Plasma-derived von Willebrand factor/factor VIII (pdVWF/FVIII; VONCENTO, CSL Behring) is a high-concentration, low-volume, high-purity concentrate, which contains a high level of high-molecular-weight multimers and a VWF/FVIII ratio of ~2.4:1....
9.
Auerswald G, Djambas Khayat C, Stasyshyn O, Iosava G, Romashevskaya I, Lopez M, et al.
J Blood Med
. 2020 Jul;
11:213-225.
PMID: 32607039
Purpose: Formulation V (VONCENTO) is a plasma-derived high-concentration/low-volume, high-purity von Willebrand factor (VWF)/factor VIII (FVIII) concentrate, originally indicated for von Willebrand disease (VWD) in adults and adolescents. This multicenter, open-label...
10.
Pan-Petesch B, Nagao A, Karim F, Tosetto A, Alvarez Roman M, Seifert W, et al.
Thromb Res
. 2020 Jun;
193:139-141.
PMID: 32559570
No abstract available.